Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
About
Careers
Partners
Contact Us
EMJ Gold
search
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
About
Careers
Partners
Contact Us
EMJ Gold
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
Hepatology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
The Evolution of Pruritus Management for People with Primary Biliary Cholangitis
10
Mins
February 2024
PBC is a chronic, progressive, immune-mediated cholestatic liver disease that involves gradual intrahepatic bile duct destruction…
Read more
6
Mins
13th January 2022
New Data on Aramchol™: Efficacy of a Higher Daily Exposure to Aramchol on Fibrosis Improvement in the ARMOR Study Open-Label Part
Non-alcoholic steatohepatitis (NASH) is the advanced form of non-alcoholic fatty liver disease, which can lead to further…
4
Mins
24th February 2020
New Data on Aramchol TM for the Treatment of Non-alcoholic Steatohepatitis: Exploring Potential for Greater Efficacy and the Effect on Glucose Metabolism
Aramchol is a liver-targeted, oral stearoyl coenzyme A desaturase 1 (SCD1) modulator that has been shown to reduce liver fat and fibrosis in patients…
9
Mins
28th May 2019
Procedural Risk of Bleeding: Does the Management of Thrombocytopenia in Chronic Liver Disease Patients Make a Difference? A Debate
Clinical studies of the TPO-R agonist lusutrombopag included a large proportion of high-risk bleeding patients and therapy with this agent has been shown…
14
Mins
27th July 2018
Primary Biliary Cholangitis in Motion Meeting
The purpose of the meeting was to work towards unified best practice in the treatment of primary biliary cholangitis (PBC). This centred on a theme of…
10
Mins
8th June 2017
A Discussion on the Management of Wilson Disease
Prof Peter Ferenci opened the meeting by providing a background to Wilson disease (WD), an enigmatic condition where no two cases are the same. He explored…
10
Mins
31st May 2016
Welcome to the Real World: Hepatitis C Virus Clinical Trials to Patient Realities
The symposium addressed the efficacy and safety of compounds currently available for treatment of hepatitis C virus (HCV) and chronic kidney disease…
11th March 2016
The Role of Sebelipase Alfa in Treating Lysosomal Acid Lipase Deficiency (LAL-D)
Lysosomal acid lipase deficiency (LAL-D), historically known as Wolman’s disease or cholesteryl ester storage disease, is a severe, underdiagnosed, and…
16th June 2015
Conquering C – Going Beyond Cure
Prof Zeuzem opened the symposium by acknowledging that there is a new era in hepatitis C virus (HCV) treatment, due to the availability of efficacious…
Loading posts...
« Previous
1
2
3
Next »